Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.54 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.54 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.54 |
| ▸ | GAPDH | P04406 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.54 |
| ▸ | STAT6 | P42226 | 1/20 | 0.54 |
| ▸ | PI4KA | P42356 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.54 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.54 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15329251 | 1.00 | ADORA1 (0.62) | ADORA1ADORA3SMN1; SMN2DPP4MEN1 | |
| SCHEMBL30582997 | 0.92 | ADORA1 (0.75) | ADORA1SMN1; SMN2DNPH1PRKAB2TRPM2 | |
| SCHEMBL15329077 | 0.92 | ADORA1 (0.75) | ADORA1SMN1; SMN2DNPH1PRKAB2TRPM2 | |
| SCHEMBL21314872 | 0.91 | ADORA1 (0.64) | ADORA1ADORA3SMN1; SMN2DPP4MEN1 | |
| SCHEMBL15329393 | 0.91 | ADORA1 (0.64) | ADORA1ADORA3SMN1; SMN2DPP4MEN1 | |
| SCHEMBL29384896 | 0.91 | ADORA1 (0.64) | ADORA1ADORA3SMN1; SMN2DPP4MEN1 | |
| SCHEMBL31544057 | 0.89 | ADORA1 (0.62) | ADORA1ADORA3SMN1; SMN2DPP4MEN1 | |
| SCHEMBL24264106 | 0.89 | ADORA1 (0.61) | ADORA1ADORA3SMN1; SMN2DPP4MEN1 | |
| SCHEMBL31744988 | 0.89 | ADORA1 (0.57) | ADORA1ADORA3SMN1; SMN2DPP4MEN1 | |
| SCHEMBL23306157 | 0.87 | ADORA1 (0.60) | ADORA1ADORA3SMN1; SMN2DPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068557-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA A/S (DK) | 2025-04-03 | — | — | WO | claimed |
| US-12553050-B2 | Compositions and methods for inhibiting cytochrome P450 family 7 subfamily a member 1 (CYP7A1) expression | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-02-17 | — | — | US | disclosed |
| US-20250297260-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 FAMILY 7 SUBFAMILY A MEMBER 1 (CYP7A1) EXPRESSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-09-25 | — | — | US | disclosed |
| EP-4594491-A2 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | Contera Pharma A/S (DK) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025068557-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA A/S (DK) | 2025-04-03 | — | — | WO | disclosed |
| WO-2024068997-A2 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA A/S (DK) | 2024-04-04 | — | — | WO | disclosed |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12553050-B2 | Compositions and methods for inhibiting cytochrome P450 family 7 subfamily a member 1 (CYP7A1) expression | CYP7A1, CYP7B1, CYP27A1 | ADORA1 804/4885ADORA3 1079/4885SMN1; SMN2 2037/4885 |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | MYOF, MYO3A, MYO3B | ADORA1 4464/4885ADORA3 4372/4885SMN1; SMN2 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.